Adaptive Biotechnologies
PublicAdaptive Biotechnologies is now publicly traded
The data on this page reflects Adaptive Biotechnologies's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 26, 2019
Last Round
Debt
Sep 12, 2022
Total Funding Raised
$1.21B
Company Overview
Adaptive Biotechnologies is a biotechnology company that develops an immune medicine platform for the diagnosis and treatment of various diseases, including cancer and autoimmune conditions.
Sector
Biotech
AI Layer
Application
Keywords
Adaptive Biotechnologies Comparables
Compare Adaptive Biotechnologies with similar companies based on industry and business-model similarity.
No public comparables are available for Adaptive Biotechnologies. Request access to learn about comparables coverage.
Request accessAdaptive Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Sep 12, 2022 | ||||
| Follow-on Offering | Jul 15, 2020 | ||||
| IPO | Jun 26, 2019 | ||||
| Series F Extension | Dec 11, 2017 | ||||
| Series F | May 6, 2015 | ||||
Series E | Jan 7, 2015 |
Key People
Founding team and executive leadership
Adaptive Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Guggenheim Securities | IPO, Follow-on Offering |
| BofA Securities | Follow-on Offering |
| OrbiMed | Debt |
| BD Biosciences | Series F |
| Walden Venture Capital | Series A |
| Viking Global Investors | Series F, Series F Extension, Series C |
| Senator Investment Group | Series F |
Adaptive Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access